



ACTION REQUIRED

National Deployment of Pathogen-Reduced Platelets: Sixth Update
 Customer Letter # 2024-10

2024-02-20

Dear Colleagues:

Further to Customer Letters [2023-13](#) and [2023-17](#), the following provides a progress update to our national deployment of pathogen-reduced platelets.

Canadian Blood Services is pleased to report that the production of pathogen reduced, **Pooled Platelets Psoralen-Treated** was fully implemented nationally as of November 20, 2023.

Effective April 8, 2024, apheresis platelets currently manufactured at our Edmonton site will be manufactured and psoralen-treated at our Calgary site. Effective April 29, 2024, apheresis platelets currently manufactured at our Saint John site will be manufactured and psoralen-treated at our Dartmouth site. **Ordering practices will not change for hospitals.**

Component name	Abbreviation
Apheresis Platelets Psoralen-treated	APPT
Apheresis Platelets PAS-E (Platelet additive solution) added, not pathogen reduced	AP in PAS

Estimated implementation timeline by site (*subject to change*):

Production Site	APPT & AP in PAS implementation timelines
Ottawa	Implemented June 12, 2023
Winnipeg	Implemented October 23, 2023
Dartmouth	Implemented December 11, 2023
Calgary	Implemented January 22, 2024
Regina	Implemented February 12, 2024
St. John's NL	March 11, 2024
Edmonton	Updated: April 8, 2024
Vancouver	April 15, 2024
Saint John NB	Updated: April 29, 2024
Brampton	May 6, 2024



**Canadian
Blood
Services**

BLOOD
PLASMA
STEM CELLS
ORGANS
& TISSUES

1800 Alta Vista Drive
Ottawa ON
K1G 4J5
Canada

Please update Laboratory Information Systems with new codes [CL 2022-34 Attachment 1](#).

All hospitals must prepare for implementation of these platelet components. Kindly share the implementation updates, component information and resource links (see next paragraph) with physicians/nursing and other affected staff in your hospital.

Please visit:

- [Clinical Guide Chapter 19: Pathogen-reduced platelets](#) for educational materials, including a Clinical Guide providing detailed information about these platelet components.
- [FAQ: Information for health professionals on apheresis platelet psoralen-treated \(APPT\) and untreated apheresis platelet in PAS-E | Professional Education \(blood.ca\)](#)
- [FAQ: Information for health professionals on pathogen-reduced platelets \(PPPT\) | Professional Education \(blood.ca\)](#)
- [Canadian Blood Services circular of Information](#)

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospital Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

David Howe
Director, Supply Chain Process Management